JHSM
Journal of Health Sciences and Medicine

Journal of Health Sciences and Medicine (JHSM) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

eISSN: 2636-8579
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
Systemic Immune-inflammation Index (SII) and Systemic Inflammatory Response Index (SIRI) as novel predictors of resistant hypertension
Abstract
Aims: Resistant hypertension (RHT) accounts for 10-15% of hypertensive patients, and diagnosis and treatment are more complex in these cases, which means a higher risk of cardiovascular complications. Although the effect of chronic systemic inflammation on the pathophysiology of RHT is known, the effective use of biomarkers is limited. This study investigated the relationship between the Systemic Immune-Inflammation Index (SII) and the Systemic Inflammatory Response Index (SIRI), which are composite inflammatory indices that can be used as markers of chronic inflammation, and RHT, testing their clinical utility and predictive value. Methods: Between April 2022 and January 2025, 256 hypertensive patients followed up at our clinic were defined as having controlled hypertension (CHT) and 244 as having RHT, for a total of 500 patients included in this cross-sectional study. SII and SIRI values were calculated from routine blood count results. Data were analyzed and compared using multivariate logistic regression, quartile analysis, limited cubic spline modeling, and receiver operating characteristic (ROC) curve analysis. Results: Significantly higher SII (480.2 vs. 361.7, p

Keywords : Resistant hypertension, systemic immune-inflammation index, systemic inflammatory response index, inflammation, biomarkers, cardiovascular risk

Download Article


1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223-237. doi:10.1038/s41581-019-0244-2
2. de la Sierra A, Ruilope LM, Staplin N, et al. Resistant hypertension and mortality: an observational cohort study. Hypertension. 2024;81:2350-2356. doi:10.1161/HYPERTENSIONAHA.124.23276
3. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912-4018. doi:10.1093/eurheartj/ehae178
4. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41:1874-2071. doi:10.1097/HJH.0000000000003480
5. Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the united states. Hypertension. 2019;73:424-431. doi:10.1161/HYPERTENSIONAHA.118. 12191
6. Parodi R, Brandani L, Romero C, Klein M. Resistant hypertension: diagnosis, evaluation, and treatment practical approach. Eur J Intern Med. 2024;123:23-28. doi:10.1016/j.ejim.2023.12.026
7. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125: 1635-1642. doi:10.1161/CIRCULATIONAHA.111.068064
8. Cardoso CRL, Salles GF. prognostic value of changes in aortic stiffness for cardiovascular outcomes and mortality in resistant hypertension. Hypertension. 2022;79:447-456. doi:10.1161/HYPERTENSIONAHA. 121.18498
9. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132-140. doi:10.1161/HYPERTENS IONAHA.110.163576
10. Tsioufis C, Kordalis A, Flessas D, et al. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens. 2011;2011:642416. doi:10.4061/2011/642416
11. Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertens Res. 2019;42:293-300. doi:10.1038/s41440-018-0158-6
12. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55:500-507. doi:10.1161/HYPERTENSIONAHA. 109.145094
13. Saco-Ledo G, Valenzuela PL, Ruilope LM, Lucia A. Physical exercise in resistant hypertension: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:893811. doi:10.3389/fcvm.2022.893811
14. Wang A, Tian X, Zuo Y, et al. Monocyte-to-lymphocyte ratio is associated with the presence and severity of resistant hypertension. J Clin Hypertens. 2022;24:1022-1029.
15. Cicero AFG, Veronesi M, Fogacci F. Dietary intervention to improve blood pressure control: beyond salt restriction. High Blood Press Cardiovasc Prev. 2021;28:547-553. doi:10.1007/s40292-021-00474-6
16. Blumenthal JA, Hinderliter AL, Smith PJ, et al. Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial. Circulation. 2021;144:1212-1226. doi:10.1161/CIRCULATIONAHA.121.055329
17. Ozemek C, Tiwari S, Sabbahi A, Carbone S, Lavie CJ. Impact of therapeutic lifestyle changes in resistant hypertension. Prog Cardiovasc Dis. 2020;63:4-9. doi:10.1016/j.pcad.2019.11.012
18. Yamada T, Kimura-Koyanagi M, Sakaguchi K, Ogawa W, Tamori Y. Obesity and risk for its comorbidities diabetes, hypertension, and dyslipidemia. Sci Rep. 2023;13:2346. doi:10.1038/s41598-023-29276-7
19. Filippou C, Tatakis F, Polyzos D, et al. Overview of salt restriction in the Dietary Approaches to Stop Hypertension (DASH) and the mediterranean diet for blood pressure reduction. Rev Cardiovasc Med. 2022;23:36. doi:10.31083/j.rcm2301036
20. Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis. Heart. 2019;105: 98-105. doi:10.1136/heartjnl-2018-313599
21. Tompson AC, Ward AM, McManus RJ, et al. Acceptability and psychological impact of out-of-office monitoring to diagnose hypertension. Br J Gen Pract. 2019;69:e389-e397. doi:10.3399/bjgp19X70 2221
22. Kasiakogias A, Tsioufis C, Dimitriadis K, et al. Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives. J Hum Hypertens. 2018;32:487-493. doi:10.1038/s41371-018-0065-y
23. Wei FF, Zhang ZY, Huang QF, Staessen JA. Diagnosis and management of resistant hypertension: state of the art. Nat Rev Nephrol. 2018;14:428-441. doi:10.1038/s41581-018-0006-6
24. Hu B, Yang XR, Xu Y, et al. Systemic Immune-Inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20:6212-6222. doi:10.1158/1078-0432.CCR-14-0442
25. Qi X, Li J, Deng H, et al. Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma. Oncotarget. 2016;7: 45283-45301. doi:10.18632/oncotarget.9942
26. Dudenbostel T, Calhoun DA. Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension. Am J Hypertens. 2017; 30:103-109. doi:10.1093/ajh/hpw105
27. Zhao D, Liu H, Dong P, Zhao J. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. Int J Cardiol. 2017;233:113-117. doi:10.1016/j.ijcard.2016.12.158
28. Bozkurt B, Aguilar D, Deswal A, et al. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure. Circulation. 2016;134:e535-e578. doi:10.1161/CIR.0000000000000450
29. Rosa J, Zelinka T, Petrák O, et al. Should all patients with resistant hypertension receive spironolactone? Curr Hypertens Rep. 2016;18:81. doi:10.1007/s11906-016-0690-1
30. Fadl Elmula FE, Jin Y, Yang WY, et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press. 2015;24:263-274. doi:10.3109/08037051.2015.1058595
Article available in :
Volume 9, Issue 1, 2026
Page : 156-163
https://doi.org/10.32322/jhsm.1831025
Article Information
Received : 26 Kas 2025
Accepted : 21 Ara 2025
Published : 05 Oca 2026
Corresponding Author :

Ertan Aydın: Giresun University

[email protected]
Citation : Aydın E, Vural A, Yılmaz E, Kurt D, Çamcı S, Gök G. Systemic Immune-inflammation Index (SII) and Systemic Inflammatory Response Index (SIRI) as novel predictors of resistant hypertension. J Health Sci Med. 2026;9(1):156-163. doi:10.32322/jhsm.1831025

Read: 52
Download : 163
Cited: 1
_Footer